Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA) (NCT06127043).

Runs
1
Findings
1
Latest Run
Mar 30, 2026, 4:31 AM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
3/30/26 UTC
Executive Summary

Public topline data for the exact Phase 2 ROSETTA ulcerative colitis trial were reported in November 2025, and the sponsor clearly framed the readout as negative: rosnilimab did not meet the primary endpoint or key secondary endpoints, showed no better efficacy than placebo at Week 12, and the UC trial was discontinued.

Sources
Sponsorglobenewswire.com11/10/25
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

AnaptysBio announced that investigational rosnilimab was safe and well tolerated but did not meet the primary endpoint of mean change from baseline in modified Mayo Score or key secondary endpoints of clinical response and clinical remission at Week 12 in the global Phase 2 trial for moderate-to-severe ulcerative colitis. The company said the UC trial will be discontinued.

View source
Web Searchfiercebiotech.com11/10/25
AnaptysBio abandons rosnilimab for ulcerative colitis after phase 2 fail

Fierce Biotech reported that AnaptysBio abandoned plans to develop rosnilimab for ulcerative colitis after the drug flunked a phase 2 study. The article states that remission rates were no better than placebo and quotes the CEO saying they were disappointed in the lack of adequate efficacy and would discontinue the UC trial.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted99% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Public topline data for the exact Phase 2 ROSETTA ulcerative colitis trial were reported in November 2025, and the sponsor clearly framed the readout as negative: rosnilimab did not meet the primary endpoint or key secondary endpoints, showed no better efficacy than placebo at Week 12, and the UC trial was discontinued.

Found Mar 30, 2026, 4:31 AMOutcome date Nov 10, 2025, 12:00 AMReviewed Mar 30, 2026, 7:04 AM
Sponsorglobenewswire.comNov 10, 2025, 12:00 AM
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
AnaptysBio announced that investigational rosnilimab was safe and well tolerated but did not meet the primary endpoint of mean change from baseline in modified Mayo Score or key secondary endpoints of clinical response and clinical remission at Week 12 in the global Phase 2 trial for moderate-to-severe ulcerative colitis. The company said the UC trial will be discontinued.
Web Searchfiercebiotech.comNov 10, 2025, 12:00 AM
AnaptysBio abandons rosnilimab for ulcerative colitis after phase 2 fail
Fierce Biotech reported that AnaptysBio abandoned plans to develop rosnilimab for ulcerative colitis after the drug flunked a phase 2 study. The article states that remission rates were no better than placebo and quotes the CEO saying they were disappointed in the lack of adequate efficacy and would discontinue the UC trial.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Mar 30, 2026, 7:04 AM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)99% confidenceReviewed Mar 30, 2026, 7:04 AM

Public topline data for the exact Phase 2 ROSETTA ulcerative colitis trial were reported in November 2025, and the sponsor clearly framed the readout as negative: rosnilimab did not meet the primary endpoint or key secondary endpoints, showed no better efficacy than placebo at Week 12, and the UC trial was discontinued.